Recancostat compositum therapy does not prevent tumor progression in young cancer patients.
Stimulated by the public discussion about an antimalignant effect of the supplement drug Recancostat compositum (200 mg glutathione, 40 mg cysteine, 50 mg anthocyanin) the drug was given in high doses to 16 young patients with intensively pretreated and measurable solid tumors for 1-30 weeks. In all patients the disease progressed, and they died 1-48 weeks following the start of the therapy. Side effects were not seen. This observation does not support the claim of an antitumor effect of Recancostat compositum.
Bode
U
U
Dept. of Pediatric Hematology/Oncology, University of Bonn, Germany. bode@uni-bonn.de
Hasan
C
C
Hülsmann
B
B
Fleischhack
G
G
D000293:Adolescent; D000328:Adult; D000872:Anthocyanins / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D000529:Complementary Therapies; D003545:Cysteine / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D004338:Drug Combinations; D005260:Female; D005978:Glutathione / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D017211:Treatment Failure
D000872:Anthocyanins; D004338:Drug Combinations; C121867:Recancostat compositum; D005978:Glutathione; D003545:Cysteine